| Previous close | 0.2600 |
| Open | 0.2600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 62.50 |
| Expiry date | 2024-01-19 |
| Day's range | 0.2600 - 0.2600 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksPfizer (PFE) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.
- Reuters
UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion
AbbVie said on Wednesday it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition. It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines. It is paying $45 per share in cash for Cerevel, which is developing drugs for Alzheimer's, Parkinson's, psychosis, epilepsy, and panic disorder.
ZacksPfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
